Sareum Holdings Plc (SAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sareum Holdings Plc (SAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12415
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, VEGFR-3 (FLT4) kinase, fatty acid synthase (FASN), tyrosine kinase 2 (TYK2), ALK kinase, FLT3 and microtubule binding agents. Sareum’s Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Pampisford, Cambridge, the UK.

Sareum Holdings Plc (SAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 11
Equity Offering 12
Sareum Raises USD1.09 Million in Private Placement of Shares 12
Sareum Holdings Raises USD1 Million in Private Placement of Shares 13
Sareum Raises USD1.6 Million in Private Placement of Shares 14
Sareum Raises USD2.2 Million in Private Placement of Shares 15
Sareum to Raise USD0.9 Million in Private Placement of Shares 16
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 17
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 18
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 19
Sareum Holdings Plc – Key Competitors 20
Sareum Holdings Plc – Key Employees 21
Sareum Holdings Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Oct 01, 2018: Sareum Holdings announce final results for the year ended 30 June 2018 23
Mar 13, 2018: Sareum Holdings: Half-yearly Results for the Six Months Ended 31 December 2017 29
Oct 19, 2017: Sareum Holdings: Final Results for the year ended 30 June 2017 34
Feb 20, 2017: Sareum Holdings Announces Half-Yearly Results For The Six Months Ended 31 December 2016 35
Corporate Communications 38
Nov 13, 2018: Sareum Holdings: Michael Owen, PhD and Clive Birch appointed as non-executive directors 38
Clinical Trials 39
Sep 26, 2018: Sareum Holdings: Potent, selective small molecule inhibitor of TYK2/JAK1 selected for further development as potential treatment for certain types of leukaemia, lymphoma and solid tumour 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sareum Holdings Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 11
Sareum Raises USD1.09 Million in Private Placement of Shares 12
Sareum Holdings Raises USD1 Million in Private Placement of Shares 13
Sareum Raises USD1.6 Million in Private Placement of Shares 14
Sareum Raises USD2.2 Million in Private Placement of Shares 15
Sareum to Raise USD0.9 Million in Private Placement of Shares 16
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 17
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 18
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 19
Sareum Holdings Plc, Key Competitors 20
Sareum Holdings Plc, Key Employees 21
Sareum Holdings Plc, Subsidiaries 22

List of Figures
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sareum Holdings Plc (SAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Burlington Northern Santa Fe, LLC:企業の戦略・SWOT・財務分析
    Burlington Northern Santa Fe, LLC - Strategy, SWOT and Corporate Finance Report Summary Burlington Northern Santa Fe, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Companhia Riograndense de Mineracao:企業の戦略・SWOT・財務情報
    Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report Summary Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • British Polythene Industries Plc
    British Polythene Industries Plc - Strategy, SWOT and Corporate Finance Report Summary British Polythene Industries Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Landmarks Berhad:企業の戦略・SWOT・財務情報
    Landmarks Berhad - Strategy, SWOT and Corporate Finance Report Summary Landmarks Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Trevena Inc (TRVN):企業の財務・戦略的SWOT分析
    Summary Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination w …
  • W.W. Grainger Inc (GWW):企業の財務・戦略的SWOT分析
    W.W. Grainger Inc (GWW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • InTouch Technologies Inc:企業の戦略的SWOT分析
    InTouch Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Pacific Hydro Pty Ltd:電力:M&Aディール及び事業提携情報
    Summary Pacific Hydro Pty Ltd (Pacific Hydro), a subsidiary of State Power Investment Corporation is an energy solutions provider that undertakes the development and operations of the renewable power projects. The company offers wind, hydro, solar and geothermal power projects at varying stages of d …
  • Puget Energy, Inc.:戦略・SWOT・企業財務分析
    Puget Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Puget Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Guararapes Confeccoes SA:企業の戦略・SWOT・財務情報
    Guararapes Confeccoes SA - Strategy, SWOT and Corporate Finance Report Summary Guararapes Confeccoes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Acorda Therapeutics, Inc.:企業の戦略・SWOT・財務情報
    Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析
    Summary Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company provides pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis …
  • ReShape Lifesciences Inc (RSLS)-医療機器分野:企業M&A・提携分析
    Summary ReShape Lifesciences Inc(ReShape Lifesciences) formerly known as EnteroMedics Inc, is a medical equipment provider that offers therapeutic and neuroregulator systems. The company designs and develops medical devices for the treatment of obesity and other disorders. It develops VBLOC therapy …
  • Opthea Ltd (OPT):企業の財務・戦略的SWOT分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Guangzhou Pharmaceuticals Corp:企業の戦略的SWOT分析
    Guangzhou Pharmaceuticals Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Coloplast A/S:企業の戦略・SWOT・財務情報
    Coloplast A/S - Strategy, SWOT and Corporate Finance Report Summary Coloplast A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • KPMG International:企業の戦略・SWOT・財務分析
    KPMG International - Strategy, SWOT and Corporate Finance Report Summary KPMG International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Industrial Alliance Insurance and Financial Services Inc.:企業の戦略・SWOT・財務情報
    Industrial Alliance Insurance and Financial Services Inc. - Strategy, SWOT and Corporate Finance Report Summary Industrial Alliance Insurance and Financial Services Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the co …
  • St. George Bank Limited:企業の戦略・SWOT・財務情報
    St. George Bank Limited - Strategy, SWOT and Corporate Finance Report Summary St. George Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Fidelity National Financial, Inc.:企業のM&A・事業提携・投資動向
    Fidelity National Financial, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fidelity National Financial, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆